Sodium-dependent phosphate transport protein 2A (Sodium-phosphate transport protein 2A), also known as Na(+)-dependent phosphate cotransporter 2A, Solute carrier family 34 member 1, Na(+)/Pi cotransporter 2A (NaPi-2a), is a protein that in humans is encoded by the SLC34A1 gene. The human NaPi-2a isoform consists of 639 amino acids. Human and rat NaPi-2a cDNAs were first isolated by expression cloning. NaPi-2a is predominantly expressed in the kidney and localizes to the apical brush border membrane of the proximal tubule. The expression is higher in early convoluted proximal tubules (S1 segments) and in juxtamedullary nephrons but spreads to the late proximal tubule (S2/S3 segments) and superficial nephrons during phosphate depletion. NaPi-2a mRNA has also been detected in brain and bone, but protein expression has not been confirmed.
|Basic Information of SLC34A1|
|Protein Name||Sodium-dependent phosphate transport protein 2A|
|Aliases||Sodium-phosphate transport protein 2A, Na(+)-dependent phosphate cotransporter 2A, NaPi-3, Sodium/phosphate cotransporter 2A, Na(+)/Pi cotransporter 2A, NaPi-2a, Solute carrier family 34 member 1, NPT2, SLC17A2|
|Organism||Homo sapiens (Human)|
In the case of SLC34A1, the regulation of SLC34 phosphate transporters has been best defined. Generally, regulation occurs primarily at the posttranscriptional level by changing the rate of synthesis and degradation and by altering the amount of NaPi-2a transporter molecules in the brush border membrane. There is little evidence that their activity in the brush border membrane to modulate the NaPi-2a transporter is altered by phosphorylation or other similar mechanisms. The biosynthetic pathways and mechanisms that control the insertion of NaPi-2a into the brush border membrane are little known. Activation of parathyroid hormone receptors downregulates NaPi-2a abundance at the brush border membrane in a few minutes by at least two different signaling pathways involving either PKA or PKC.
Fig.1 Localization of renal phosphate cotransporters in rodent kidney. (Wagner, 2014)
The article identifies a novel homozygous mutation in the phosphate transporter SLC34A1 in hypophosphatemia and nephrocalcinosis.
Authors in this group found that the small molecule LC-1 can be used as a potent inhibitor of hNpt2A and it is possible to develop potent specific hNpt2A inhibitors to control phosphate overloading for hyperphosphatemia therapy.
The article reports that Na/phosphate transporter gene Slc34a1 selectively generates endo-siRNAs in murine tissues.
The article reveals that the early differentiation between SLC34A1 and CYP24A1 (24-hydroxylase) defects is critical for targeted therapy in patients with idiopathic infantile hypercalcemia.
The article reports that a single amino acid substitution in Npt2a may lead to improper translocation of the protein to the cell membrane, disturbance of phosphate homeostasis, and renal calcification.
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC34A1 antibody development services.
As a leading service provider, Creative Biolabs is proud to present our professional service in membrane protein preparation and help you with the research of membrane proteins. Please do not hesitate to inquire us for more details.